Tenax Therapeutics Inc (TENX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tenax Therapeutics Inc (TENX) has a cash flow conversion efficiency ratio of -0.095x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.15 Million) by net assets ($96.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tenax Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Tenax Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TENX current and long-term liabilities for a breakdown of total debt and financial obligations.
Tenax Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tenax Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Horizon Space Acquisition II Corp. Ordinary share
NASDAQ:HSPT
|
-0.004x |
|
Advero Properties SOCIMI S.A.
MC:YADV
|
0.008x |
|
BitNine Co. Ltd.
KQ:357880
|
-0.127x |
|
Hennessy Ad
NASDAQ:HNNA
|
0.007x |
|
Trias Sentosa Tbk
JK:TRST
|
0.029x |
|
Intiland Development Tbk
JK:DILD
|
0.037x |
|
Llorente & Cuenca S.A.
MC:LLYC
|
0.283x |
|
Awea Mechantronic Co Ltd
TW:1530
|
0.014x |
Annual Cash Flow Conversion Efficiency for Tenax Therapeutics Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Tenax Therapeutics Inc from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see TENX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $91.99 Million | $-14.81 Million | -0.161x | +77.92% |
| 2023-12-31 | $8.10 Million | $-5.90 Million | -0.729x | +90.94% |
| 2022-12-31 | $1.49 Million | $-12.01 Million | -8.048x | -214.65% |
| 2021-12-31 | $4.24 Million | $-10.86 Million | -2.558x | -27.58% |
| 2020-12-31 | $4.63 Million | $-9.27 Million | -2.005x | -0.09% |
| 2019-12-31 | $3.77 Million | $-7.56 Million | -2.003x | -328.73% |
| 2018-12-31 | $11.77 Million | $-5.50 Million | -0.467x | +65.82% |
| 2017-12-31 | $8.88 Million | $-12.14 Million | -1.367x | -47.62% |
| 2016-12-31 | $17.14 Million | $-15.87 Million | -0.926x | -473.89% |
| 2015-12-31 | $60.42 Million | $-9.75 Million | -0.161x | -44.39% |
| 2014-12-31 | $82.89 Million | $-9.26 Million | -0.112x | 0.00% |
| 2013-12-31 | $82.89 Million | $-9.26 Million | -0.112x | +31.20% |
| 2012-12-31 | $30.30 Million | $-4.92 Million | -0.162x | -101.68% |
| 2011-12-31 | $-871.46K | $-8.40 Million | 9.643x | +338.84% |
| 2010-12-31 | $2.13 Million | $-8.59 Million | -4.037x | -281.02% |
| 2009-12-31 | $3.83 Million | $-4.06 Million | -1.060x | -207.36% |
| 2008-12-31 | $6.60 Million | $-2.28 Million | -0.345x | -113.89% |
| 2007-12-31 | $-458.25K | $-1.14 Million | 2.483x | +121.52% |
| 2006-12-31 | $186.22K | $-2.15 Million | -11.537x | -449.29% |
| 2005-12-31 | $948.40K | $-1.99 Million | -2.100x | -71.48% |
| 2004-12-31 | $1.45 Million | $-1.77 Million | -1.225x | +32.60% |
| 2003-12-31 | $1.15 Million | $-2.09 Million | -1.817x | -18.33% |
| 2002-12-31 | $1.24 Million | $-1.90 Million | -1.536x | -239.02% |
| 2001-12-31 | $3.39 Million | $-1.54 Million | -0.453x | -190.35% |
| 2000-12-31 | $5.85 Million | $-913.30K | -0.156x | -101.95% |
| 1999-12-31 | $-100.00K | $-800.00K | 8.000x | +588.53% |
| 1998-12-31 | $351.55K | $-575.69K | -1.638x | -153.05% |
| 1997-12-31 | $-282.51K | $-872.15K | 3.087x | +20.56% |
| 1996-12-31 | $-597.60K | $-1.53 Million | 2.561x | 0.00% |
| 1995-12-31 | $-597.60K | $-1.53 Million | 2.561x | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatini… Read more